Renoprotective Effects of DPP-4 Inhibitors

• Egile Nagusiak: Daiji Kawanami (Egilea), Yuichi Takashi (Egilea), Hiroyuki Takahashi (Egilea), Ryoko Motonaga (Egilea), Makito Tanabe (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2021-02-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD) worldwide. Dipeptidyl peptidase (DPP)-4 inhibitors are widely used in the treatment of patients with type 2 diabetes (T2D). DPP-4 inhibitors reduce glucose levels by inhibiting degradation of incretins. DPP-4 is a u...